On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Cannabinoid influence on cytokine profile in multiple sclerosis.|
|Author(s)||Katona S, Kaminski E, Sanders H, Zajicek J.|
|Journal, Volume, Issue||Clin. Exp. Immunol. 2005;140(3):580-585.|
|Major outcome(s)||There were no significant effects of cannabinoids on the cytokine profiles examined.|
Cannabinoids have been suggested as possessing immunomodulatory properties, and cannabinoid receptors are present on leucocytes. Clinically, there is some evidence that cannabinoids may be therapeutically useful in treating multiple sclerosis, which is generally believed to be an autoimmune condition. This paper reports data derived from the Cannabinoids in MS (CAMS) study, which was the largest randomized controlled trial yet conducted to evaluate the therapeutic efficacy of cannabinoids. We found no evidence for cannabinoid influence on serum levels of interferon (IFN)-γ, interleukin (IL)-10, IL-12 or C-reactive protein as measured using enzyme-linked immunosorbent assay (ELISA), in comparison to control values. Mitogenic stimulation experiments also failed to demonstrate any significant reduction in percentage of CD3+, IFN-γ producing cells after exposure to cannabinoids in vivo, although numbers were small. Further work is needed to establish the functional significance of cannabinoid receptors on immune cells.
|Participants||100 patients with multiple sclerosis|
|Type of publication||Medical journal|
|Address of author(s)||Department of Immunology, Derriford Hospital, Plymouth PL6 8DH|